Showing results (241-250 of 274) with videos related to
Sort By:
Pageof 28
The Journal of Pathology|December 6, 2013
The genomic landscape of oesophagogastric junctional adenocarcinomaIrene Y Chong, David Cunningham, Louise J Barber, et al.The Oncologist|November 7, 2022
SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer TherapyDavid K Lau, Maria Aresu, Timothy Planche, et al.Oncotarget|October 15, 2017
Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatmentSing Y Moorcraft, Thomas Jones, Brian A Walker, et al.Lancet (London, England)|October 8, 2013
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialCharles S Fuchs, Jiri Tomasek, Cho Jae Yong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2020
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell LymphomaLeo I Gordon, Jason B Kaplan, Rakesh Popat, et al.Journal for Immunotherapy of Cancer|April 16, 2019
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoidsReyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, et al.The Lancet. Oncology|June 9, 2016
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialScott J Antonia, José A López-Martin, Johanna Bendell, et al.Leukemia & Lymphoma|December 6, 2021
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphomaAhmad S Halwani, Carlos Panizo, Iris Isufi, et al.The Lancet. Haematology|April 29, 2018
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trialMary Gleeson, Clare Peckitt, Ye Mong To, et al.The Lancet. Oncology|February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.Pageof 28